Section Arrow
ALVR.NASDAQ
- AlloVir
(Financial Status)
Quotes are at least 15-min delayed:2024/05/14 04:30 EDT
Last
 0.7501
-0.0354 (-4.51%)
Day High 
0.808 
Prev. Close
0.7855 
1-M High
0.825 
Volume 
2.29M 
Bid
0.72
Ask
0.813
Day Low
0.58 
Open
0.79 
1-M Low
0.72 
Market Cap 
90.26M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.8 
20-SMA 0.78 
50-SMA 0.76 
52-W High 6.12 
52-W Low 0.58 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.83/--
Enterprise Value
106.91M
Balance Sheet
Book Value Per Share
1.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NVAXNovavax13.11+4.23+47.64%-- 
DNAGinkgo Bioworks Holdings0.8407+0.0798+10.49%-- 
ACIUAC Immune SA3.3+0.99+42.86%-- 
JAGXJaguar Health0.290795-0.001305-0.45%-- 
TVGNTevogen Bio Holdings1+0.0155+1.57%-- 
Quotes are at least 15-min delayed:2024/05/14 04:30 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.